Skip to main content

Cormorant Asset Management — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

209
Companies
$19.7B
Total invested
$134.8M
Avg. check
21
Industries
Biotechnology 19Health Care 17Medical 9Therapeutics 8Medical Device 8Pharmaceutical 7+15 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 209
Rapport Therapeutics
September 2025

Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.

Biotechnology · Boston$250.0M Post-IPO Equity
Ventyx Biosciences
September 2024

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.

Biopharma · San Diego$27.0M Post-IPO Equity
RayzeBio
September 2022

RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.

Biotechnology · San Diego$160.0M Series D
Avidity Biosciences
September 2025

Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.

Biotechnology · San Diego$690.0M Post-IPO Equity
Atia Vision
August 2022

Atia Medical focuses on advancing eye care through the innovation of ophthalmic devices, diagnostics, and pharmaceuticals.

Biotechnology · Campbell$28.6M Venture - Series Unknown
Axonics Modulation Technologies
August 2022

Axonics Modulation Technologies is a pre-revenue company developing novel implantable neuromodulation.

Health Diagnostics · Irvine$111.7M Post-IPO Equity
GondolaBio
August 2024

GondolaBio researches, develops and manufactures pharmaceutical products.

Biotechnology · Palo Alto$300.0M Venture - Series Unknown
Bigfoot Biomedical
August 2022

Bigfoot Biomedical is a medical device company changing diabetes care for people with insulin-requiring diabetes.

Artificial Intelligence (AI) · MilpitasConvertible Note
Prime Medicine
August 2025

Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.

Biotechnology · Cambridge$5.0M Post-IPO Equity
Epicrispr Biotechnologies
August 2026

Epic Bio's strength is a relentless focus on ushering in a new era of gene regulation.

Biotechnology · South San Francisco$90.0M Series C
Cue Biopharma
July 2026

Cue Biopharma is a developer of a productive platform for the treatment of cancer and autoimmune disease.

Biopharma · Cambridge$50.0M Post-IPO Equity
Fore Biotherapeutics
July 2026

Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.

Biotechnology · Philadelphia$67.4M Series D
Strata Oncology
July 2021

Strata Oncology is a precision oncology company dedicated to transforming cancer care.

Biotechnology · Ann Arbor$90.0M Series C
Navigantis
July 2024

Navigantis empowers physicians to deliver uncompromised neurovascular care by creating a new frontier in surgical robotics.

Health Care · Miami$12.0M Series A
Crystalys Therapeutics
July 2026

Crystalys Therapeutics is a clinical-stage biopharmaceutical company that develops targeted therapies for gout and hyperuricemia.

Biopharma · San Diego$130.0M Series B
Freenome
July 2026

Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.

Biotechnology · South San Francisco$240.0M Post-IPO Equity
Clearside Biomedical
July 2026

Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.

Biotechnology · Alpharetta$3.0M Post-IPO Debt
Erasca
July 2026

Erasca is a developer of oncology drugs intended to provide precision oncology options.

Biotechnology · San Diego$632.5M Post-IPO Equity
Neurogene
July 2026

Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.

Biotechnology · New York$125.0M Post-IPO Equity
Tango Therapeutics
June 2026

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Biotechnology · Cambridge$600.0M Post-IPO Equity
Elevation Oncology
June 2023

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.

Biopharma · New York$50.0M Post-IPO Equity
Vigil Neuroscience
June 2024

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.

Biotechnology · Cambridge$40.0M Post-IPO Equity
Myra Vision
June 2023

Myra Vision develops a treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma.

Health Care · Campbell$25.0M Series B
MoonLake Immunotherapeutics
June 2026

MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.

Biotechnology · Zug$200.0M Post-IPO Equity

Where Cormorant Asset Management invests

Biotechnology19
Health Care17
Medical9
Therapeutics8
Medical Device8
Pharmaceutical7

About Cormorant Asset Management's portfolio

How many companies has Cormorant Asset Management invested in?

Cormorant Asset Management has invested in 209 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Cormorant Asset Management invest in?

Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Medical Device. The firm invests across 21 different industry categories.

What is Cormorant Asset Management's largest investment?

Among tracked funding rounds, Avidity Biosciences received $690.0M in a Post-IPO Equity round. Cormorant Asset Management's total known invested capital is $19.7B.

What is the average investment size for Cormorant Asset Management?

Cormorant Asset Management's average investment size is $134.8M across its portfolio of 209 companies.

What are Cormorant Asset Management's most recent investments?

Recent Cormorant Asset Management portfolio additions include Rapport Therapeutics, Ventyx Biosciences, RayzeBio, Avidity Biosciences, Atia Vision. These companies were founded in 2020 or later.

Reach the founders behind these 209 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →